Skip to content

Study · In vitro (cells) · 1993

2 results

High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines.

Emons G, Schröder B, Ortmann O, Westphalen S, Schulz KD, Schally AV

The Journal of clinical endocrinology and metabolism1 Dec 1993Cited by 128 (Europe PMC)

PMID8263128 (opens in a new tab)DOI10.1210/jcem.77.6.8263128 (opens in a new tab)PepBankPUB-08263128
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In HEC-1A endometrial cancer cells, cetrorelix produced time- and dose-dependent antiproliferative effects.

    In plain wordsIn cells, cetrorelix reduced HEC-1A proliferation relative to controls, with time- and dose-dependent effects.

    Peptide
    Cetrorelix
    Outcome
    DecreaseHEC-1A cell proliferation
    Study

    humann: not reported in source

    HEC-1A endometrial cancer cells
    Comparator
    Control cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similar time- and dose-dependent antiproliferative effects were obtained in both cell lines with the LHRH antagonist SB-75 (cetrorelix).
    1 context sentence
    Summary · context
    In this study we evaluated whether binding sites for LHRH are also present in the human endometrial cancer cell lines HEC-1A and Ishikawa and if such sites could mediate antiproliferative effects of LHRH analogs.
  2. 02LabIn vitro (cells)Efficacy outcome

    In Ishikawa endometrial cancer cells, cetrorelix produced time- and dose-dependent antiproliferative effects.

    In plain wordsIn cells, cetrorelix reduced Ishikawa proliferation relative to controls, with time- and dose-dependent effects.

    Peptide
    Cetrorelix
    Outcome
    DecreaseIshikawa cell proliferation
    Study

    humann: not reported in source

    Ishikawa endometrial cancer cells
    Comparator
    Control cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similar time- and dose-dependent antiproliferative effects were obtained in both cell lines with the LHRH antagonist SB-75 (cetrorelix).
    1 context sentence
    Summary · context
    In this study we evaluated whether binding sites for LHRH are also present in the human endometrial cancer cell lines HEC-1A and Ishikawa and if such sites could mediate antiproliferative effects of LHRH analogs.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.